Co-hosted by HealthEconomics.com, this unique, live streamed panel webinar will feature four of our top HEOR thought leaders in conversation with moderator and HealthEconomics.com CEO Patti Peeples.
Joining Patti will be Dr. Peter Neumann, Precision Xtract Consultant and Director of the Center for the Evaluation of Value and Risk in Health (CEVR), Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Dr. Anupam Bapu Jena, Precision Xtract Scientific Advisor and Associate Professor at Harvard Medical School; Dr. Jeroen Jansen, […]
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
In a new MedAd News feature article on the influence of value assessments, Precision Xtract’s Jacki Chou and Zac Stillerman provide their insights on the growing influence of ICER, and how manufacturers can be more proactive in shaping favorable assessments of their new treatments.
Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
For more information, or to learn how to change your cookies preferences, please click here.